J Gynecol Oncol.  2012 Apr;23(2):75-77. 10.3802/jgo.2012.23.2.75.

Three ongoing intraperitoneal chemotherapy trials in ovarian cancer

• Fujiwara K

• KMID: 2177577
• DOI: http://doi.org/10.3802/jgo.2012.23.2.75

Abstract

No abstract available.

MeSH Terms

Ovarian Neoplasms

Reference

1. Fujiwara K, Armstrong D, Morgan M, Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2007. 17:1–20.

2. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996. 335:1950–1955.

3. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001. 19:1001–1007.

4. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006. 354:34–43.

5. NCI clinical announcement: intraperitoneal chemotherapy for ovarian cancer [Internet]. National Cancer Institute. 2006. cited 2012 Mar 10. Bethesda, MD: National Cancer Institute;Available from: http://ctep.cancer.gov/highlights/docs/clin_annc_010506.pdf.

6. Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006. 100:27–32.

7. Kim MJ, Jung YW, Seong SJ, Yoon BS, Kim ML, Joo WD, et al. Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer. J Gynecol Oncol. 2012. 23:91–97.

8. Fujiwara K. Can carboplatin replace cisplatin for intraperitoneal use? Int J Gynecol Cancer. 2008. 18:Suppl 1. 29–32.

9. Fujiwara K, Sakuragi N, Suzuki S, Yoshida N, Maehata K, Nishiya M, et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol. 2003. 90:637–643.

10. Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, Degeest K, et al. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2011. 121:264–268.

11. Fujiwara K, Aotani E, Hamano T, Nagao S, Yoshikawa H, Sugiyama T, et al. A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer. Jpn J Clin Oncol. 2011. 41:278–282.

12. Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy: a comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin-a Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol. 2005. 99:591–596.

13. Fujiwara K, Nagao S, Kigawa J, Noma J, Akamatsu N, Miyagi Y, et al. Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study. Int J Gynecol Cancer. 2009. 19:834–837.